Lo Andrew's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Jan 3, 2022
- Accession no.
- 0000899243-22-000188
- Filed
- Jan 3, 2022
- Trade date
- Dec 29-30, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $98.8K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lo AndrewCIK 0001679076 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 29, 2021 | Common Stock | PPurchaseAcquired | +6,000 | $12.90 | +$77,400 | 46,599 | Direct | |
| Dec 30, 2021 | Common Stock | PPurchaseAcquired | +1,500 | $14.30 | +$21,450 | 48,099 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.